Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Standard of Care 2Methods 2Interviews as Topic 2Educational Status 2Early Intervention, Educational 2Counseling 2Blood Specimen Collection 2zilucoplan 1sacituzumab govitecan 1rozanolixizumab 1pembrolizumab 1oxycodone-acetaminophen 1ibrutinib 1futibatinib 1erdafitinib 1enzalutamide 1enfortumab vedotin 1dynorphin-converting endopeptidase 1durvalumab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1avelumab 1Vinblastine 1Tramadol 1Surgical Procedures, Operative 1Stents 1Specimen Handling 1Semen Analysis 1Robotic Surgical Procedures 1Relaxation Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × brexucabtagene autoleucel × 30 days × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡